Genetic Risk of Osteonecrosis of the Jaw (ONJ) in Patients With Metastatic Cancer
This study seeks to identify risk factors associated with the development of a jaw condition seen in patients with cancer treated with certain medications.
Bone and Bones
|Study Design:||Observational Model: Case Control
Time Perspective: Retrospective
|Official Title:||Genetic Risk of Osteonecrosis of the Jaw (ONJ) in Patients With Metastatic Cancer|
paraffin embedded tissue block and/or WBC
|Study Start Date:||August 2010|
Patient with cancer involving the bone treated with osteoclast inhibitor (bisphosphonate) and has developed ONJ
Patient with cancer involving the bone treated with osteoclast inhibitor (bisphosphonate) and has NOT developed ONJ
The goal of this research is to build an index of risk for estimating an individual's risk of developing osteonecrosis of the jaw (ONJ). The bisphosphonates are an important supportive therapy in the care of patients with metastatic bone disease; they are able to prevent catastrophic events such as fracture and spinal cord compression. However, ONJ has been associated with the use of the bisphosphonates and ONJ carries significant morbidity. Presently, there are insufficient data to calculate the ONJ risk benefit ratio of bisphoshonate use. An ONJ risk assessment tool would improve both the oncologist's and the dental health professional the ability to anticipate and potentially mitigate oral toxicities from bisphosphonate therapy.
This protocol consists of a case (ONJ) control (no ONJ) study to identify factors associated with the risk of ONJ and to build an index predictive of an individual's risk of developing ONJ. The index of ONJ risk will be comprised of clinical, epidemiologic and genetic factors
|United States, Michigan|
|University of Michigan|
|Ann Arbor, Michigan, United States, 48109|
|Principal Investigator:||Catherine Van Poznak, MD||University of Michigan|